NOD1 inhibition by Nodinitib-1 together with ETBF clearance by metronidazole (MNZ) increased the chemosensitivity of breast cancer by targeting breast cancer stem cells (BCSCs), providing a promising therapeutic rationale to overcome chemoresistance in breast cancer. This evidence concerns the gene NOD1 and breast carcinoma.